MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.

ABSTRACT:

Purpose

Radiotherapy is commonly used to treat a variety of solid tumors. However, improvements in the therapeutic ratio for several disease sites are sorely needed, leading us to assess molecularly targeted therapeutics as radiosensitizers. The aim of this study was to assess the wee1 kinase inhibitor, MK-1775, for its ability to radiosensitize human tumor cells.

Experimental design

Human tumor cells derived from lung, breast, and prostate cancers were tested for radiosensitization by MK-1775 using clonogenic survival assays. Both p53 wild-type and p53-defective lines were included. The ability of MK-1775 to abrogate the radiation-induced G₂ block, thereby allowing cells harboring DNA lesions to prematurely progress into mitosis, was determined using flow cytometry and dete

SUBMITTER: Bridges KA 

PROVIDER: S-EPMC3167033 | biostudies-literature | 2011 Sep

REPOSITORIES: biostudies-literature